Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren's syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?

RMD Open. 2019 Jan 11;5(1):e000701. doi: 10.1136/rmdopen-2018-000701. eCollection 2019.

Sofie L M Blokland¹, Maarten R Hillen², Catharina G K Wichers^{1

2}, Maili Zimmermann^{1

2}, Aike A Kruize^{1

2}, Timothy R D J Radstake^{1

2}, Jasper C A Broen^#^{1

2}, Joel A G van Roon^#^{1

2}

¹ Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
² Laboratory of Translational Immunology, Department of Immunology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.

^# Contributed equally.

No abstract available

Keywords: B cells; Sjögren’s syndrome; T cells; mTOR; rapamycin.

MeSH terms